Business Wire

94% of Businesses Acknowledge a Privacy Skills Gap

17.1.2023 20:37:00 EET | Business Wire | Press release

Share

Privacy is a critical component of digital trust – it contributes to a more positive reputation and fewer cybersecurity incidents for the companies that prioritise it. Global digital trust association, ISACA, believes that businesses are aware of its significance; according to its 2023 “Privacy in Practice” report published today, 87% of organisations in Europe offer privacy awareness training to employees. But they’re missing the mark as most (94%) companies recognise a privacy skills gap within their business.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230117005916/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

ISACA surveyed more than 1,800 professionals worldwide—including 375 in Europe—who work in data privacy or have detailed knowledge of the data privacy function within their organisations to demonstrate current perspectives on privacy staffing, organisation structure, frameworks and policies, budgets, training, and data breaches. Learn more about the key findings and the business benefits of privacy by design at www.isaca.org/privacy-month-2023. (Graphic: ISACA)

ISACA’s “Privacy in Practice” report explores the state of enterprise privacy by examining trends around privacy teams, privacy-related challenges, privacy by design and the future of privacy.

The report reveals that as it stands, more than half (59%) of technical privacy teams in Europe are understaffed. Building these departments is a challenge, with 1 in 5 businesses saying it takes them more than six months to fill a technical privacy position and 41% saying their privacy budgets are underfunded.

The most reported privacy failures include a lack of training or poor training (49%); data breaches (38%); and not practicing privacy by design (39%). With just 38% of business leaders confident in their organisation’s ability to ensure the privacy of its sensitive data, businesses need to change their approach to closing the privacy skills gap or risk jeopardising their relationships with customers and damaging the reputation of the business.

Chris Dimitriadis, Global Chief Strategy Officer, ISACA says: “Privacy professionals play a key role in establishing digital trust. As technology advances, introducing new complexities and threats and as the cyberthreat landscape increases in size and sophistication, demand for these individuals is only going to grow. Heightened privacy skills demand is good news for candidates with privacy technology knowledge but also bad news for businesses that are struggling to close the privacy skills gap. As our new research highlights, businesses need to consider changing their training programmes and adopt privacy by design to limit the number of privacy breaches, build digital trust, and set the business up for long term success.”

Tony Hughes, ISACA Emerging Trends Working Group Member, adds: “Only searching for candidates with specific experience and technical privacy skills is an outdated mindset – it immediately limits businesses to a small pool of people. Instead, organisations need to lean on reskilling people in non-privacy roles, using contract employees and focusing on individuals with the right soft skills to reduce the privacy skills gap.”

Notes to Editors

All figures are based on fieldwork conducted by ISACA. Fieldwork was undertaken in Q4 2022, amongst 1890 global privacy professionals, including 375 in Europe.

ISACA’s Privacy in Practice report is now available to download here.

About ISACA

For more than 50 years, ISACA has equipped individuals and enterprises with the knowledge, credentials, education, training and community to progress their careers, transform their organisations, and build a more trusted and ethical digital world. ISACA leverages the expertise of its more than 165,000 members who work in digital trust fields such as information security, governance, assurance, risk, privacy and quality, with a presence in 188 countries, including 225 chapters worldwide. Through its foundation One In Tech, ISACA supports IT education and career pathways for under resourced and underrepresented populations.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

olivia.parkinson@firstlightgroup.io, 07526565507

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Doubtless Pet Care Launches to Provide Peace of Mind to Pet Parents and Help Their Pets Live Happier, Healthier Lives29.6.2026 11:15:00 EEST | Press release

Doubtless launches today with the goal of helping more pet parents across the world access quality care for the pets they love. The company brings together a leading global portfolio of pet insurance brands with a growing range of connected solutions designed to support pet parents at every stage of their pet’s life. With over 4,000 employees, Doubtless insures 6 million pets across 10 markets in North America, Europe and the United Kingdom. “Uncertainty about the financial commitments associated with having a pet should never keep families from experiencing the joy of a life with pets,” said Dirk Beeckman, CEO of Doubtless. “By harnessing the power of our international footprint, we are building on our leadership in pet insurance to create a global suite of solutions for pet parents, veterinarians and industry partners that makes pet care easier to access, navigate and manage. This will ultimately give pet parents better guidance, greater confidence and more control at every point in

Coolbrook Secures Business Finland Funding to Accelerate Electrification for the Global Steel Industry29.6.2026 11:00:00 EEST | Press release

Coolbrook, a transformational technology company dedicated to decarbonising heavy industry and industrial processes, has been awarded research and development funding by Business Finland to accelerate the decarbonisation of steel production. The grant supports Coolbrook’s participation in the FutSteel project, a core component of the Sustainable World through Steels ecosystem led by SSAB. Within the broader FutSteel project, Coolbrook’s project scope amounts to €5 million, of which €2.5 million is covered by grant funding awarded to Coolbrook. The funding will enable Coolbrook to further accelerate and develop its next-generation RotoDynamic Heater™ (RDH™) technology, specifically tailored for high-temperature steel industry applications. The project focuses on integrating RDH™ technology into critical stages of the steel production chain, including blast furnace processes, electrified reheating, hot-stove air pre-heating, hybrid-heating concepts, decarbonised Direct Reduced Iron (DRI)

Samsung Bioepis Announces Positive Preliminary Phase 1 and Phase 3 Data for SB27, a Proposed Biosimilar to Keytruda (Pembrolizumab)29.6.2026 10:19:00 EEST | Press release

Samsung Bioepis Co., Ltd. announced today that the Phase 1 and Phase 3 studies on SB27, a proposed biosimilar to Keytruda1 (pembrolizumab), have met their primary endpoints. “We are excited to announce preliminary results from the Phase 1 and Phase 3 studies for SB27, our pembrolizumab biosimilar candidate. These topline positive results reinforce our scientific expertise and leadership in biosimilar development,” said Donghoon Shin, Executive Vice President and Head of Clinical Sciences Division at Samsung Bioepis. “We are on track to complete both Phase 1 and Phase 3 studies within this year. Leveraging our robust quality management system, we remain committed to advancing our biosimilar portfolio to broaden access to life-saving biologic medicines for patients with unmet needs.” Pembrolizumab is a humanized monoclonal antibody that acts as an immune checkpoint inhibitor by targeting and blocking the programmed cell death protein 1 (PD-1) receptor on T cells. It is used to treat vari

IQM Named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment29.6.2026 10:00:00 EEST | Press release

IQM today announced it has been named a Major Player in the IDC MarketScape: Worldwide Quantum Computing 2026 Vendor Assessment. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260629748732/en/ IQM named a major player in the IDC MarketScape IQM believes this recognition comes as institutions worldwide move quantum computing out of shared cloud access and into infrastructure they own and operate themselves. IQM calls this Production Quantum: full-stack, open-architecture superconducting systems deployed on premises, inside customers' own data centers and HPC environments, where organizations own the hardware, build internal expertise, and run quantum processors alongside their existing classical infrastructure. According to the IDC MarketScape, "For institutions building long-term quantum programs, this means the workflows and intellectual property developed on IQM hardware remain portable." The report further advises: "Consi

Zambon Announces Positive CHMP Opinion for Hopledo® (IPX203) for Adults with Parkinson’s Disease and Moderate to Severe Motor Fluctuations29.6.2026 10:00:00 EEST | Press release

Zambon today announced that the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization by the European Medicines Agency (EMA) for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/DDC inhibitor-based treatment regimens. CHMP recommendation is based on data from the Phase 3 RISE-PD trial, which compared Hopledo® with immediate release levodopa/carbidopa (LD/CD) formulation in patients with Parkinson’s disease and moderate to severe motor fluctuations. In the study, Hopledo® demonstrated a significant increase in Good ON time over immediate release LD/CD with fewer daily doses and a comparable safety profile1. Hopledo® is a first-in-class, oral, modified-release formulation of LD/CD designed for the treatment of fluctuations of Parkinson’s diseas

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye